Exiris presents data on novel cytotoxic peptide-drug conjugates for tumor targeted therapy, generated in collaboration with the University of Bielefeld and Italfarmaco within the Horizon 2020 MAGICBULLET project. Two lectures... read more →
Exiris is awarded a grant from Regione Lazio Life 2020, POR FESR LAZIO 2014 – 2020 – Progetti integrati (0.44 M€), with the project: Therapeutic Antibody Service Technology (TASTE)
Exiris, in collaboration with the Italian Institute of Health (ISS), Rome and with Aldevron Freiburg Germany, has generated a novel antibody that shows efficacy against colon cancer stem cell and... read more →
Data are presented on novel cryptophycin-based antibody- and peptide-drug conjugates for tumor targeted therapy, generated in collaboration with the University of Bielefeld
Exiris signs agreements with the Italian Institute of Health (ISS) and with Aldevron on the development of novel anticancer agents. According to two separate agreements, Exiris acquires exclusive rights to,... read more →
Exiris, in collaboration with Prof N. Sewald from the University of Bielefeld, Germany, has identified a novel class of drugs that shows picomolar activity against stem cells from colon and... read more →
Exiris signs Research Collaboration Agreement with Italfarmaco (1.4 M€).
Exiris is awarded a Marie Skłodowska-Curie European Training Network (ETN) grant in the context of the Horizon 2020 MAGICBULLET project (3.75 M€).
Exiris presents data on novel cancer stem cell targets at the EMBO Workshop: Cancer stem cells 20 years later: Achievements, controversies, emerging concepts and technologies.